Significance of KRAS/PAK1/Crk pathway in non-small cell lung cancer oncogenesis

BMC Cancer

Volumn 15, Issue 1, 2015, Pages

  Mortazavi, Fariborz ^a,b,c   Lu, Jie ^b   Phan, Ryan ^a   Lewis, Michael ^a   Trinidad, Kenny ^a   Aljilani, Amir ^a   Pezeshkpour, Gholamhossein ^a   Tamanoi, Fuyuhiko ^b,c  

^a VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

c Crk; Cell adhesion; E cadherin; KRAS; Lung cancer; PAK1 kinase; Signal transduction

Indexed keywords

CATENIN; K RAS PROTEIN; ONCOPROTEIN; P21 ACTIVATED KINASE 1; PROTEIN P120; UVOMORULIN; CADHERIN; CRK PROTEIN, HUMAN; DELTA CATENIN; KRAS PROTEIN, HUMAN; P21 ACTIVATED KINASE; PAK1 PROTEIN, HUMAN; PROTEIN P21;

A549 CELL LINE; ARTICLE; CANCER STAGING; CELL MOTILITY; CELL PROLIFERATION; CELL STRUCTURE; CONTROLLED STUDY; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG CANCER CELL LINE; LUNG CARCINOGENESIS; NON SMALL CELL LUNG CANCER; ONCOGENE K RAS; PAK1 GENE; PROTEIN DEPHOSPHORYLATION; PROTEIN PHOSPHORYLATION; PROTEIN PRENYLATION; PROTO ONCOGENE CRK; SIGNAL TRANSDUCTION; CARCINOGENESIS; GENE EXPRESSION REGULATION; GENETICS; LUNG TUMOR; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY; PRENYLATION; TUMOR CELL LINE;

CADHERINS; CARCINOGENESIS; CARCINOMA, NON-SMALL-CELL LUNG; CATENINS; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; P21-ACTIVATED KINASES; PHOSPHORYLATION; PRENYLATION; PROTO-ONCOGENE PROTEINS C-CRK; PROTO-ONCOGENE PROTEINS P21(RAS); SIGNAL TRANSDUCTION;

EID: 84935010215     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-015-1360-4     Document Type: Article

References (26)

1. Chow HY, Jubb AM, Koch JN, Jaffer ZM, Stepanova D, Campbell DA, et al. p21-Activated kinase 1 is required for efficient tumor formation and progression in a Ras-mediated skin cancer model. Cancer Res. 2012;72:5966-75.
2. McDaniel AS, Allen JD, Park SJ, Jaffer ZM, Michels EG, Burgin SJ, et al. Pak1 regulates multiple c-Kit mediated Ras-MAPK gain-in-function phenotypes in Nf1+/- mast cells. Blood. 2008;112:4646-54.
3. Singhal R, Kandel ES. The response to PAK1 inhibitor IPA3 distinguishes between cancer cells with mutations in BRAF and Ras oncogenes. Oncotarget. 2012;3:700-8.
4. Tabusa H, Brooks T, Massey AJ. Knockdown of PAK4 or PAK1 inhibits the proliferation of mutant KRAS colon cancer cells independently of RAF/MEK/ERK and PI3K/AKT signaling. Mol Cancer Res. 2013;11:109-21.
5. Rettig M, Trinidad K, Pezeshkpour G, Frost P, Sharma S, Moatamed F, et al. PAK1 kinase promotes cell motility and invasiveness through CRK-II serine phosphorylation in non-small cell lung cancer cells. PLoS One. 2012;7:e42012.
6. Mayer BJ, Hamaguchi M, Hanafusa H. A novel viral oncogene with structural similarity to phospholipase C. Nature. 1988;332:272-5.
7. Mayer BJ, Hamaguchi M, Hanafusa H. Characterization of p47gag-crk, a novel oncogene product with sequence similarity to a putative modulatory domain of protein-tyrosine kinases and phospholipase C. Cold Spring Harb Symp Quant Biol. 1988;53(Pt 2):907-14.
8. Takino T, Nakada M, Miyamori H, Yamashita J, Yamada KM, Sato H. CrkI adapter protein modulates cell migration and invasion in glioblastoma. Cancer Res. 2003;63:2335-7.
9. Mortazavi F, Dubinett S, Rettig M. c-Crk proto-oncogene contributes to transcriptional repression of p120-catenin in non-small cell lung cancer cells. Clin Exp Metastasis. 2011;28:391-404.
10. Davis MA, Ireton RC, Reynolds AB. A core function for p120-catenin in cadherin turnover. J Cell Biol. 2003;163:525-34.
11. Ireton RC, Davis MA, van HJ, Mariner DJ, Barnes K, Thoreson MA, et al. A novel role for p120 catenin in E-cadherin function. J Cell Biol. 2002;159:465-76.
12. Xiao K, Allison DF, Buckley KM, Kottke MD, Vincent PA, Faundez V, et al. Cellular levels of p120 catenin function as a set point for cadherin expression levels in microvascular endothelial cells. J Cell Biol. 2003;163:535-45.
13. Chan PM, Lim L, Manser E. PAK is regulated by PI3K, PIX, CDC42, and PP2Calpha and mediates focal adhesion turnover in the hyperosmotic stress-induced p38 pathway. J Biol Chem. 2008;283:24949-61.
14. Lightcap CM, Sun S, Lear JD, Rodeck U, Polenova T, Williams JC. Biochemical and structural characterization of the Pak1-LC8 interaction. J Biol Chem. 2008;283:27314-24.
15. Castellano S, Fiji HD, Kinderman SS, Watanabe M, Leon P, Tamanoi F, et al. Small-molecule inhibitors of protein geranylgeranyltransferase type I. J Am Chem Soc. 2007;129:5843-5.
16. Chan LN, Fiji HD, Watanabe M, Kwon O, Tamanoi F. Identification and characterization of mechanism of action of p 61-E7, a novel phosphine catalysis-based inhibitor of geranylgeranyltransferase-I. PLoS One. 2011;6:e26135.
17. Lu J, Chan L, Fiji HD, Dahl R, Kwon O, Tamanoi F. In vivo antitumor effect of a novel inhibitor of protein geranylgeranyltransferase-I. Mol Cancer Ther. 2009;8:1218-26.
18. Watanabe M, Fiji HD, Guo L, Chan L, Kinderman SS, Slamon DJ, et al. Inhibitors of protein geranylgeranyltransferase I and Rab geranylgeranyltransferase identified from a library of allenoate-derived compounds. J Biol Chem. 2008;283:9571-9.
19. Zimonjic DB, Chan LN, Tripathi V, Lu J, Kwon O, Popescu NC, et al. In vitro and in vivo effects of geranylgeranyltransferase I inhibitor P61A6 on non-small cell lung cancer cells. BMC Cancer. 2013;13:198.
20. Basso AD, Kirschmeier P, Bishop WR. Lipid posttranslational modifications. Farnesyl transferase inhibitors. J Lipid Res. 2006;47:15-31.
21. Rowinsky EK. Lately, it occurs to me what a long, strange trip it's been for the farnesyltransferase inhibitors. J Clin Oncol. 2006;24:2981-4.
22. Caraglia M, Budillon A, Tagliaferri P, Marra M, Abbruzzese A, Caponigro F. Isoprenylation of intracellular proteins as a new target for the therapy of human neoplasms: preclinical and clinical implications. Curr Drug Targets. 2005;6:301-23.
23. Caraglia M, D'Alessandro AM, Marra M, Giuberti G, Vitale G, Viscomi C, et al. The farnesyl transferase inhibitor R115777 (Zarnestra) synergistically enhances growth inhibition and apoptosis induced on epidermoid cancer cells by Zoledronic acid (Zometa) and Pamidronate. Oncogene. 2004;23:6900-13.
24. Caraglia M, Marra M, Viscomi C, D'Alessandro AM, Budillon A, Meo G, et al. The farnesyltransferase inhibitor R115777 (ZARNESTRA) enhances the pro-apoptotic activity of interferon-alpha through the inhibition of multiple survival pathways. Int J Cancer. 2007;121:2317-30.
25. Baines AT, Xu D, Der CJ. Inhibition of Ras for cancer treatment: the search continues. Future Med Chem. 2011;3:1787-808.
26. Lobell RB, Omer CA, Abrams MT, Bhimnathwala HG, Brucker MJ, Buser CA, et al. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models. Cancer Res. 2001;61:8758-68.